A Phase 3, INterVentional, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of DCC-2618 In Patients With AdvanCed Gastrointestinal Stromal TUmorS Who Have Received Treatment With Prior Anticancer Therapies
Phase of Trial: Phase III
Latest Information Update: 10 Aug 2018
At a glance
- Drugs DCC 2618 (Primary)
- Indications Gastrointestinal stromal tumours
- Focus Registrational; Therapeutic Use
- Acronyms INVICTUS
- Sponsors Deciphera Pharmaceuticals
- 04 Jan 2018 According to a Deciphera Pharmaceuticals media release, company expects to report top-line results in 2019 and if successful, this pivotal Phase III study could serve as the basis for a New Drug Application (NDA).
- 04 Jan 2018 Status changed from not yet recruiting to recruiting.
- 21 Nov 2017 Status changed from planning to not yet recruiting.